, median (range)				58 (24-91)		313
umatoid nodules (% positive)				38.6%		306
iographic erosions (% positive)				75.7%		247
((% using)				52.4%		313
-a inhibitors (% using)				37.4%	37.4% 313	
er DMARDs (% using)				36.1%	36.1% 313	
IDs (% using)				50.5%		313
roids (% using)				29.1%		313
an DAS28-CRP changed by -0.72 (P<0.0001), indicating an overall clinical ovement in the patient cohort over three years. Interestingly, significanges occurred in DAS28-CRP and all three composite variables (CRP, SJC and between Baseline and Year 1. Changes in the same variables between Year 2 did not reach significance (Table 3).  1 Changes in clinical variables from baseline to year 1 and from year year 2.						
	Baseline - Year 1			Year 1 - Year 2		
ble	N	Change	P-value	N	Change	e P-value
cian's Global Assessment	302	-0.84	<0.001	286	-0.25	< 0.05
(mg/L)	307	-2.62	< 0.05	301	2.35	_
CCP (U)	250	3.35	_	262	56.5	< 0.001
an Inited Count (20)	207	2 22	-0.001	207	0.60	